Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor
- PMID: 3055785
- DOI: 10.1530/acta.0.1190321
Interleukin-1 induced impairment in pancreatic islet oxidative metabolism of glucose is potentiated by tumor necrosis factor
Abstract
Recent observations suggest that human interleukin-1 (IL-1) causes functional impairment and death of pancreatic B-cells. This action seems to be potentiated by another cytokine, tumor necrosis factor (TNF). In the present investigation, the effects of recombinant human (r)IL-1 (10, 30 and 150 pmol/l), and a combination of rIL-1 and human rTNF (25 micrograms/l), on islet glucose metabolism were examined in the presence of D-[5-3H] and D-[6-14C) glucose. The utilization of glucose was not affected by rIL-1 or rIL-1 plus rTNF. However, rIL-1 induced a 40% decrease in glucose oxidation, which was further potentiated by the addition of rTNF. rTNF alone did not impair islet glucose utilization or oxidation. It is concluded that rIL-1 induces a perturbation of islet glucose handling, mainly at the mitochondrial level. This impairment in the oxidative metabolism of glucose is further increased by the addition of rTNF.
Similar articles
-
Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity.J Immunol. 1987 Dec 15;139(12):4077-82. J Immunol. 1987. PMID: 3320203
-
Species differences in human and rat islet sensitivity to human cytokines. Monoclonal anti-interleukin-1 (IL-1) influences on direct and indirect IL-1-mediated islet effects.Cytokine. 1991 Mar;3(2):117-24. doi: 10.1016/1043-4666(91)90031-8. Cytokine. 1991. PMID: 1888882
-
Differential sensitivity to beta-cell secretagogues in cultured rat pancreatic islets exposed to human interleukin-1 beta.Endocrinology. 1989 Aug;125(2):752-9. doi: 10.1210/endo-125-2-752. Endocrinology. 1989. PMID: 2666106
-
Human interleukin-1 beta induced stimulation of insulin release from rat pancreatic islets is accompanied by an increase in mitochondrial oxidative events.Diabetologia. 1989 Nov;32(11):769-73. doi: 10.1007/BF00264905. Diabetologia. 1989. PMID: 2687062
-
Interleukin-1 beta depletes insulin messenger ribonucleic acid and increases the heat shock protein hsp70 in mouse pancreatic islets without impairing the glucose metabolism.Endocrinology. 1990 Nov;127(5):2290-7. doi: 10.1210/endo-127-5-2290. Endocrinology. 1990. PMID: 2171911
Cited by
-
The immunologic insult in type 1 diabetes.Springer Semin Immunopathol. 1993;14(3):253-74. doi: 10.1007/BF00195977. Springer Semin Immunopathol. 1993. PMID: 8438209 Review. No abstract available.
-
Heat shock protein induction in rat pancreatic islets by recombinant human interleukin 1 beta.Diabetologia. 1991 Mar;34(3):150-6. doi: 10.1007/BF00418268. Diabetologia. 1991. PMID: 1884886
-
Impact of metabolic activity of beta cells on cytokine-induced damage and recovery of rat pancreatic islets.Acta Diabetol. 1995 Dec;32(4):217-24. doi: 10.1007/BF00576253. Acta Diabetol. 1995. PMID: 8750759
-
Protection against cytokine toxicity through endoplasmic reticulum and mitochondrial stress prevention by prostacyclin synthase overexpression in insulin-producing cells.J Biol Chem. 2010 Apr 9;285(15):11121-8. doi: 10.1074/jbc.M109.054775. Epub 2010 Feb 16. J Biol Chem. 2010. PMID: 20159982 Free PMC article.
-
Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.Diabetes Care. 2009 Jul;32(7):1244-9. doi: 10.2337/dc09-0054. Epub 2009 Apr 14. Diabetes Care. 2009. PMID: 19366957 Free PMC article. Clinical Trial.